Tamer Sallam

Tamer Sallam

Auto-generated profile, based on publicly available information

Tamer Sallam

Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Cell Metabolism
Verified
Journal Article
Closed access
CLChanghan Lee
Changhan Lee
JZJennifer Zeng
Jennifer Zeng
BDBrian G. Drew
Brian G. Drew
TSTamer Sallam
Tamer Sallam
Alejandro MartinAlejandro Martin
Alejandro Martin
PCPinchas Cohen
Pinchas Cohen

1 February 2022 in Trends in Genetics
Verified
Journal Article
Open access
RKRyan L. Kan
Ryan L. Kan
JCJianjun Chen
Jianjun Chen
TSTamer Sallam
Tamer Sallam
Epigenetic modifications occur on genomic DNA and histones to influence gene expression. More recently, the discovery that mRNA undergoes similar chemical modifications that powerfully impact transcript turnover and translation adds another layer of dynamic gene regulation. Central to precise and synchronized regulation of gene expression is intricate crosstalk between multiple checkpoints involved in transcript biosynthesis and processing. There are more than 100 internal modifications of RNA in mammalian cells. The most common is N6-methyladenosine (m6A) methylation. Although m6A is established to influence RNA stability dynamics and translation efficiency, rapidly accumulating evidence shows significant crosstalk between RNA methylation and histone/DNA epigenetic mechanisms. These interactions specify transcriptional outputs, translation, recruitment of chromatin modifiers, as well as the deployment of the m6A methyltransferase complex (MTC) at target sites. In this review, we dissect m6A-orchestrated feedback circuits that regulate histone modifications and the activity of regulatory RNAs, such as long noncoding (lnc)RNA and chromosome-associated regulatory RNA. Collectively, this body of evidence suggests that m6A acts as a versatile checkpoint that can couple different layers of gene regulation with one another.

1 February 2015 in Cell Metabolism
Verified
Journal Article
Closed access
BPBrian W. Parks
Brian W. Parks
TSTamer Sallam
Tamer Sallam
MMMargarete Mehrabian
Margarete Mehrabian
NPNikolas Psychogios
Nikolas Psychogios
SHSimon T. Hui
Simon T. Hui
ALAldons J. Lusis
Aldons J. Lusis

5 January 2018 in Circulation Research
Verified
Journal Article
Closed access
PDF file
TSTamer Sallam
Tamer Sallam
JSJaspreet Sandhu
Jaspreet Sandhu
PTPeter Tontonoz
Peter Tontonoz
Despite significant improvements during the past 3 decades, cardiovascular disease remains a leading worldwide health epidemic. The recent identification of a fascinating group of mediators known as long noncoding RNAs (lncRNAs) has provided a wealth of new biology to explore for cardiovascular risk mitigation. lncRNAs are expressed in a highly context-specific fashion, and multiple lines of evidence implicated them in diverse biological processes. Indeed, abnormalities of lncRNAs have been directly linked with human ailments, including cardiovascular biology and disease. Of particular interest to the cardiovascular research community, dysregulation in lncRNA regulatory circuits have been associated with cardiac pathological hypertrophy, vascular disease, cell fate programming and development, atherosclerosis, dyslipidemia, and metabolic syndrome. Although techniques in interrogating noncoding RNAs are rapidly evolving, a major challenge in studying lncRNAs remains navigating through multiple technical constraints. In this review, we provide a road map for lncRNA discovery and interrogation in biological systems relevant to cardiovascular disease and highlight approaches to decipher their modes of action.

11 May 2016 in Nature
Verified
Journal Article
Open access
PDF file
TSTamer Sallam
Tamer Sallam
MJMarius C. Jones
Marius C. Jones
TGThomas Gilliland
Thomas Gilliland
LZLi Zhang
Li Zhang
XWXiaohui Wu
Xiaohui Wu
PTPeter Tontonoz
Peter Tontonoz
The activation of lipid X receptors (LXRs) in mouse liver not only promotes cholesterol efflux but also inhibits cholesterol synthesis simultaneously; this is mediated by the lipid-responsive long non-coding RNA LeXis, which is induced by a Western diet and orchestrates crosstalk between LXRs and the cholesterol biosynthetic pathway. Liver X receptors (LXRs) and sterol regulatory element-binding proteins (SREBPs) are transcription factors that act as key regulators of cellular and systemic cholesterol homeostasis, controlling cholesterol efflux and cholesterol production, respectively. This study shows that the activation of LXRs in mouse liver not only promotes cholesterol efflux but also inhibits cholesterol synthesis. This activation is mediated by the lipid-responsive long non-coding RNA LeXis, which is induced by a Western diet and orchestrates crosstalk between LXRs and the cholesterol biosynthetic pathway. Liver X receptors (LXRs) are transcriptional regulators of cellular and systemic cholesterol homeostasis. Under conditions of excess cholesterol, LXR activation induces the expression of several genes involved in cholesterol efflux1, facilitates cholesterol esterification by promoting fatty acid synthesis2, and inhibits cholesterol uptake by the low-density lipoprotein receptor3. The fact that sterol content is maintained in a narrow range in most cell types and in the organism as a whole suggests that extensive crosstalk between regulatory pathways must exist. However, the molecular mechanisms that integrate LXRs with other lipid metabolic pathways are incompletely understood. Here we show that ligand activation of LXRs in mouse liver not only promotes cholesterol efflux, but also simultaneously inhibits cholesterol biosynthesis. We further identify the long non-coding RNA LeXis as a mediator of this effect. Hepatic LeXis expression is robustly induced in response to a Western diet (high in fat and cholesterol) or to pharmacological LXR activation. Raising or lowering LeXis levels in the liver affects the expression of genes involved in cholesterol biosynthesis and alters the cholesterol levels in the liver and plasma. LeXis interacts with and affects the DNA interactions of RALY, a heterogeneous ribonucleoprotein that acts as a transcriptional cofactor for cholesterol biosynthetic genes in the mouse liver. These findings outline a regulatory role for a non-coding RNA in lipid metabolism and advance our understanding of the mechanisms that coordinate sterol homeostasis.

12 February 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TSTamer Sallam
Tamer Sallam
MJMarius Jones
Marius Jones
BTBrandon J Thomas
Brandon J Thomas
XWXiaohui Wu
Xiaohui Wu
TGThomas Gilliland
Thomas Gilliland
PTPeter Tontonoz
Peter Tontonoz